MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for Intermediate AMD at ARVO 2026 on May 06, 2026 AMD Desiccation Glycogen storage disease type II MingMed Biotechnology Phase II QA102 +
EyePoint Pharmaceuticals Reports Positive Phase 2 Results for DURAVYU in Wet AMD, Challenging Established Anti-VEGF Therapies on February 10, 2025 AMD anti-VEGF therapy Clinical Trials DURAVYU EyePoint Pharmaceuticals Glycogen storage disease type II Movement Prices vorolanib +